Insmed Incorporated (INSM)

About Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

As of November 3, 2026, Insmed Incorporated (INSM) stock fell to $105.78, down 3.23% (-$3.53) versus the previous close. On the day, shares have traded between $104.32 and $111.11. That puts INSM in the lower third of its 52-week range of $90.39 to $212.75. Insmed Incorporated operates in the pharmaceutical preparations space and carries a market capitalization of roughly $24.70 billion, with about 1.65 million shares changing hands.

Latest INSM news

• Insmed (INSM) Lifts Guidance After Earnings As Fair Value Debate Heats UpYahoo Finance· Oct 31, 12:09 PM ET
• Insmed (INSM) Begins BRINSUPRI Sales In JapanYahoo Finance· Oct 30, 9:17 PM ET
• INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceYahoo Finance· Oct 30, 9:29 AM ET
• Insmed Incorporated Q3 2026 Earnings Call Summaryapp.moby.co· Oct 30, 8:30 AM ET
• Why Did Insmed Stock Jump?trefis.com· Oct 30, 7:15 AM ET
• Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”tikr.com· Oct 29, 2:40 PM ET
• What Insmed (INSM) Said on Its Q3 Earnings Callmarketbeat.com· Oct 29, 2:14 PM ET
• Insmed (INSM) Q3 2026 Earnings Call Transcriptfool.com· Oct 29, 2:13 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want INSM headlines, alerts and AI research in one place? Create a free account →

• $INSM expensive but great

  @Rxmaxxing· Nov 3, 12:29 PM ET

• $INSM I hold two great bios just getting hammered

  @RandyLaheyCoreyTrevor· Nov 3, 11:21 AM ET

• $INSM BMO Capital analyst Conor MacKay maintains Insmed with a buy rating, and maintains the target price at $192.

  @pianoman439· Nov 3, 10:57 AM ET· Bullish

• $INSM Guggenheim lowered its price target on Insmed Inc. to $201 from $205 while maintaining a Buy rating on the stock. The firm made the adjustment following changes to its company model and detailed product launch model after the company’s third-quarter results. Insmed repor…

  @bemore· Nov 2, 9:29 AM ET

• Guggenheim⬇️ $INSM's PT to $201 from $205 and reiterated Buy & Top Pick [MRK CSLLY GSK AZN UTHR LQDA ARMP] Guggenheim said in its note: https://x.com/Quantumup1/status/2117238349756833941?a=VyLRdK3Pp3n2Sa_wmB0&s=20

  @Quantumup· Nov 2, 7:52 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →